Canada Gazette, Part I, Volume 158, Number 22: Regulations Amending the Cannabis Regulations (Harmonization with Certain Provisions of the Controlled Substances Regulations)
June 1, 2024
Statutory authority
Cannabis Act
Sponsoring department
Department of Health
REGULATORY IMPACT ANALYSIS STATEMENT
For the Regulatory Impact Analysis Statement, see the Controlled Substances Regulations.
PROPOSED REGULATORY TEXT
Notice is given that the Governor in Council proposes to make the annexed Regulations Amending the Cannabis Regulations (Harmonization with Certain Provisions of the Controlled Substances Regulations) under subsection 139(1) of the Cannabis Act footnote a.
Interested persons may make representations concerning the proposed Regulations within 60 days after the date of publication of this notice. They are strongly encouraged to use the online commenting feature that is available on the Canada Gazette website but if they use email, mail or any other means, the representations should cite the Canada Gazette, Part I, and the date of publication of this notice, and be sent to the Regulatory, Legislative and Economic Affairs Division, Strategic Policy Directorate, Controlled Substances and Cannabis Branch, Department of Health, Address Locator: 0302I, 150 Tunney’s Pasture Driveway, Ottawa, Ontario K1A 0K9 (email: cannabis.consultation@hc-sc.gc.ca).
Ottawa, May 23, 2024
Wendy Nixon
Assistant Clerk of the Privy Council
Regulations Amending the Cannabis Regulations (Harmonization with Certain Provisions of the Controlled Substances Regulations)
Amendments
1 (1) The definition nécessaire d’essai in subsection 1(2) of the French version of the Cannabis Regulations footnote 1 is repealed.
(2) The definition combination product in subsection 1(2) of the Regulations is replaced by the following:
- combination product
- means a product, consisting of a device and a prescription drug, that has a drug identification number. (produit mixte)
(3) The definition test kit in subsection 1(2) of the English version of the Regulations is replaced by the following:
- test kit
- means a kit
- (a) that contains cannabis and an adulterating or denaturing agent;
- (b) that is used to test for cannabis; and
- (c) the contents of which are not intended or likely to be consumed or administered. (trousse d’essai ou nécessaire d’essai)
(4) Paragraph (c) of the definition prescription drug in subsection 1(2) of the Regulations is replaced by the following:
- (c) that has a drug identification number. (drogue sur ordonnance)
(5) Subsection 1(2) of the Regulations is amended by adding the following in alphabetical order:
- brand name,
- in relation to a prescription drug or a combination product, has the same meaning as in subsection C.01.001(1) of the Food and Drug Regulations. (nom commercial)
- common name,
- except in Part 7 and section 226.1, has the same meaning as in subsection C.01.001(1) of the Food and Drug Regulations. (nom usuel)
- drug identification number
- means the identification number assigned under paragraph C.01.014.2(1)(a) of the Food and Drug Regulations. (identification numérique)
- former Narcotic Control Regulations
- means the regulations made by Order in Council P.C. 1961-1133 of August 9, 1961 and registered as SOR/61-344. (ancien Règlement sur les stupéfiants)
(6) Subsection 1(2) of the French version of the Regulations is amended by adding the following in alphabetical order:
trousse d’essai ou nécessaire d’essai Trousse qui, à la fois :
- a) contient du cannabis ainsi qu’un agent d’adultération ou de dénaturation;
- b) est utilisée pour le dépistage du cannabis;
- c) ne contient rien qui soit destiné à être consommé ou à être administré ou qui soit susceptible de l’être. (test kit)
2 Subparagraph 4(1)(c)(viii) of the Regulations is replaced by the following:
- (viii) a person to which an exemption has been granted under section 140 of the Act in relation to the cannabis or the class of cannabis that is sold or distributed, or
3 The Regulations are amended by adding the following after section 4:
Distribution to pharmacist for destruction
4.1 (1) For the purposes of subparagraph 9(1)(a)(i) and (iii) and paragraph 9(1)(b) of the Act, an individual who has cannabis in their possession is authorized to distribute the cannabis to a pharmacist, other than one who is practising in a hospital, for the purpose of its destruction if
- (a) the individual obtained the cannabis in accordance with the Act or these Regulations; or
- (b) the individual obtained the cannabis from another individual who they have reasonable grounds to believe obtained it in accordance with the Act or these Regulations.
Deeming — controlled substance
(2) Cannabis that is distributed to a pharmacist in accordance with subsection (1) is deemed, for the purpose of its destruction, to be a controlled substance within the meaning of subsection 1(2) of the Controlled Substances Regulations.
4 Subsection 12(2) of the Regulations is replaced by the following:
Responsibilities and knowledge
(2) The master grower is responsible for the cultivation, propagation and harvesting of cannabis and must have sufficient knowledge of the provisions of the Act and these Regulations that are applicable to those activities to properly carry out their duties.
5 Subsection 15(2) of the Regulations is replaced by the following:
Responsibilities and knowledge
(2) The master grower is responsible for the cultivation, propagation and harvesting of cannabis and must have sufficient knowledge of the provisions of the Act and these Regulations that are applicable to those activities to properly carry out their duties.
6 (1) Paragraph 23(2)(a) of the Regulations is replaced by the following:
- (a) have sufficient knowledge of the provisions of the Act and these Regulations that are applicable to the activities authorized by the licence for analytical testing to properly carry out their duties;
(2) Paragraph 23(2)(b) of the English version of the Regulations is replaced by the following:
- (b) have knowledge and experience relevant to their duties; and
(3) Subparagraph 23(2)(c)(i) of the English version of the Regulations is replaced by the following:
- (i) a diploma, certificate or credential awarded by a post-secondary educational institution in Canada in a field or occupation that is relevant to their duties, such as chemistry, biology, pharmaceutical or scientific regulatory affairs, laboratory management or laboratory technician, or
(4) The portion of subparagraph 23(2)(c)(ii) of the Regulations before clause (A) is replaced by the following:
- (ii) a diploma, certificate or credential awarded by a foreign educational institution in a field or occupation referred to in subparagraph (i) and one of the following assessments that establishes the equivalency of the diploma, certificate or credential to one of the documents referred to in that subparagraph:
(5) Clauses 23(2)(c)(ii)(A) and (B) of the French version of the Regulations are replaced by the following:
- (A) une attestation d’équivalence au sens du paragraphe 73(1) du Règlement sur l’immigration et la protection des réfugiés,
- (B) une attestation d’équivalence délivrée par une institution ou une organisation chargée de faire des attestations d’équivalence et reconnue par une province.
7 Subsection 37(2) of the Regulations is replaced by the following:
Responsibilities and knowledge
(2) The responsible person is responsible for the activities conducted under the licence and must have sufficient knowledge of the provisions of the Act and these Regulations that are applicable to those activities to properly carry out their duties.
8 (1) The definitions brand name and common name in section 139 of the Regulations are repealed.
(2) The definition licensed dealer in section 139 of the Regulations is replaced by the following:
- licensed dealer
- has the same meaning as in subsection 1(1) of the Controlled Substances Regulations. (distributeur autorisé)
(3) Section 139 of the Regulations is amended by adding the following in alphabetical order:
- specialized in destruction
- has the same meaning as in subsection 1(1) of the Controlled Substances Regulations. (spécialisé en destruction)
9 (1) Paragraph 143(1)(g) of the Regulations is replaced by the following:
- (g) a pharmacist, if the drug is a prescription drug;
(2) Paragraph 143(1)(i) of the Regulations is replaced by the following:
- (i) a hospital employee, if the drug is a prescription drug;
(3) Paragraphs 143(2)(a) and (b) of the Regulations are replaced by the following:
- (a) they receive a written order that specifies
- (i) the proper name or common name of the drug or, in the case of a prescription drug, its brand name and drug identification number, and
- (ii) the quantity of the drug to be supplied;
- (b) the order is signed and dated
- (i) in the case of a prescription drug to be provided to a hospital employee or a practitioner in a hospital, by the pharmacist in charge of the hospital’s pharmacy or by a practitioner authorized by the individual in charge of the hospital to sign the order, and
- (ii) in any other case, by the person to which the drug is to be sold; and
- (c) the holder verifies the signature, if it is unknown to them.
(4) Subsection 143(3) of the Regulations is replaced by the following:
Exception — pharmacist and practitioner
(3) It is prohibited for a holder of a cannabis drug licence to sell or distribute
- (a) a prescription drug to a pharmacist who is named in a notice issued under subsection 181(2) or (4); or
- (b) a drug containing cannabis to a practitioner who is named in a notice issued under subsection 189(2) or (4).
10 (1) Subsections 146(4) and (5) of the Regulations are replaced by the following:
Witness — licensed dealer specialized in destruction
(4) The following individuals are qualified to witness the destruction of cannabis by a licensed dealer specialized in destruction:
- (a) the senior person in charge or qualified person in charge, as those terms are defined in subsection 1(1) of the Controlled Substances Regulations, or an alternate qualified person in charge designated under subsection 9(2) of those Regulations; and
- (b) a person who works for or provides services to the licensed dealer specialized in destruction and holds a senior position.
Attestation by witnesses
(5) For each instance that they destroy cannabis, the holder of a cannabis drug licence or the licensed dealer specialized in destruction, as the case may be, must obtain an attestation signed and dated by two of the witnesses referred to in paragraph (1)(b) or (2)(b) stating that they witnessed the destruction and that the cannabis was destroyed in accordance with a method referred to in paragraph (1)(a) or (2)(a).
(2) Paragraph 146(6)(b) of the Regulations is replaced by the following:
- (b) in the case of a drug containing cannabis
- (i) its proper name or common name or, in the case of a prescription drug, its brand name, and
- (ii) its strength per unit;
(3) Subsection 146(7) of the Regulations is replaced by the following:
Retention period
(7) The holder of a cannabis drug licence and the licensed dealer specialized in destruction must retain the record and the attestation for at least two years after the day on which the cannabis is destroyed.
11 (1) The portion of subparagraph 150(3)(b)(iii) of the Regulations before clause (A) is replaced by the following:
- (iii) hold a diploma, certificate or credential that is awarded by a foreign educational institution in a field or occupation referred to in subparagraph (ii) and one of the following assessments that establishes the equivalency of the diploma, certificate or credential to one of the documents referred to in that subparagraph:
(2) Clauses 150(3)(b)(iii)(A) and (B) of the French version of the Regulations are replaced by the following:
- (A) une attestation d’équivalence au sens du paragraphe 73(1) du Règlement sur l’immigration et la protection des réfugiés,
- (B) une attestation d’équivalence délivrée par une institution ou une organisation chargée de faire des attestations d’équivalence et reconnue par une province;
(3) Paragraph 150(3)(d) of the Regulations is replaced by the following:
- (d) they have sufficient knowledge of the provisions of the Act and these Regulations that are applicable to the activities authorized by the licence to properly carry out their duties.
(4) Paragraph 150(4)(c) of the English version of the Regulations is replaced by the following:
- (c) the individual has sufficient knowledge acquired from a combination of education, training or work experience to properly carry out their duties.
12 The French version of the Regulations is amended by replacing « visée à » with « prévue à » in paragraphs 151(2)(a) to (d).
13 (1) Subparagraph 152(2)(b)(i) of the Regulations is replaced by the following:
- (i) an attestation, signed and dated by the proposed individual, stating that the proposed individual is not ineligible for a reason specified in section 151,
(2) Subparagraph 152(2)(c)(ii) of the Regulations is replaced by the following:
- (ii) an attestation, signed and dated by the senior person in charge, stating that the proposed individual has the knowledge and experience required under paragraphs 150(3)(c) and (d), and
(3) The portion of subparagraph 152(2)(c)(iii) before clause (A) of the French version of the Regulations is replaced by the following:
- (iii) dans le cas où l’individu proposé ne satisfait pas à l’exigence visée au sous-alinéa 150(3)b)(i) :
14 The heading of Division 2 of Part 8 of the Regulations is replaced by the following:
Possession, Pharmacists, Practitioners, Hospitals and Licensed Dealers
15 (1) Paragraph 159(a) of the Regulations is replaced by the following:
- (a) a practitioner who is entitled to practise in the province in which they possess the drug or a holder of a cannabis drug licence, if they require the drug for their business or profession;
(2) Paragraphs 159(c) to (f) of the Regulations are replaced by the following:
- (c) an individual who possesses a quantity of the drug that exceeds the applicable limit under the Act and has obtained the drug for their own use or for their animal from a practitioner or in accordance with a prescription that was not issued or obtained in contravention of these Regulations;
- (d) an individual who possesses a quantity of the drug that exceeds the applicable limit under the Act and has reasonable grounds to believe that the drug was obtained by another individual in accordance with paragraph (c) if the possession is for the purpose of its return or destruction;
- (e) a licensed dealer, other than a licensed dealer specialized in destruction, if the possession is for the purpose of selling or distributing it to a licensed dealer specialized in destruction;
- (f) a licensed dealer specialized in destruction, if the possession is for the purpose of its destruction;
(3) Section 159 of the Regulations is renumbered as subsection 159(1) and is amended by adding the following:
Possession — prescription drug
(2) The following persons, if they have obtained a prescription drug either in accordance with these Regulations, or from a person that is exempt under section 140 of the Act from the application of subsections 9(1) and (2) and 10(1) and (2) of the Act with respect to that drug, are authorized to possess the drug:
- (a) a pharmacist, if they require the drug for their business or profession; or
- (b) a hospital employee or a practitioner in a hospital.
16 Sections 160 and 161 of the Regulations are replaced by the following:
Possession — quantity allowed
160 Any quantity of drug containing cannabis that an individual is authorized to possess under paragraph 159(1)(c) or (d) is in addition to any other quantity of cannabis that the individual is authorized to possess under the Act.
17 Sections 163 and 164 of the Regulations are replaced by the following:
Exemption — section 21 of Act
163 A person is exempt from the application of section 21 of the Act if they display, refer to or otherwise use the brand name of a prescription drug, or the name of the holder of the drug identification number for a prescription drug, directly or indirectly in a promotion that is used in the sponsorship of a person, entity, event, activity or facility.
Exemption — section 22 of Act
164 A person is exempt from the application of section 22 of the Act if they display on a facility, as part of the name of the facility or otherwise, if the facility is used for a sports or cultural event or activity, the brand name of a prescription drug or the name of the holder of the drug identification number for a prescription drug.
18 Paragraph 170(a) of the Regulations is replaced by the following:
- (a) the brand name and quantity of the drug received;
19 (1) The portion of section 171 of the Regulations before paragraph (a) is replaced by the following:
Sale, distribution and administration
171 Subject to section 174, a pharmacist is authorized to sell, distribute or administer a prescription drug to a person
(2) Paragraph 171(a) of the English version of the Regulations is replaced by the following:
- (a) if the person is exempt under section 140 of the Act with respect to the possession of that drug; or
(3) Subparagraph 171(b)(ii) of the French version of the Regulations is replaced by the following:
- (ii) il vérifie la signature du praticien lorsqu’il ne la reconnaît pas.
20 (1) The portion of subsection 172(1) of the Regulations before paragraph (a) is replaced by the following:
Return and destruction
172 (1) A pharmacist is authorized to sell or distribute a prescription drug, in accordance with a written order, to
(2) Paragraph 172(2)(a) of the Regulations is replaced by the following:
- (a) the brand name, quantity and strength per unit of the drug; and
21 Section 173 of the Regulations is repealed.
22 The portion of subsection 174(1) of the Regulations before paragraph (a) is replaced by the following:
Prohibited activities
174 (1) It is prohibited for a pharmacist to
23 The portion of subsection 175(1) of the Regulations before paragraph (a) is replaced by the following:
Distribution — hospital
175 (1) Subject to section 174, a pharmacist may distribute a prescription drug to a hospital employee or a practitioner in a hospital in accordance with a written order signed and dated by
24 The portion of section 176 of the Regulations before paragraph (a) is replaced by the following:
Security obligations
176 A pharmacist must, with respect to a prescription drug on their premises or for which the pharmacist is responsible,
25 Section 177 of the Regulations is replaced by the following:
Record keeping
177 (1) A pharmacist who sells, distributes or administers a prescription drug must retain a record of the following information:
- (a) in the case of a sale, distribution or administration to a person in accordance with a written order or prescription,
- (i) the name of the pharmacist,
- (ii) the name and address of the pharmacist or practitioner who issued the order or the practitioner who issued the prescription,
- (iii) the name and address of the person to which the drug was sold, distributed or administered,
- (iv) the brand name, quantity and form of the drug,
- (v) the date on which the drug was sold, distributed or administered, and
- (vi) in the case of a prescription, the number assigned to it; and
- (b) in the case of a sale, distribution or administration to a person who is exempt under section 140 of the Act with respect to the possession of the drug,
- (i) the name of the pharmacist,
- (ii) the name and address of the person to which the drug was sold, distributed or administered,
- (iii) the brand name, quantity and form of the drug, and
- (iv) the date on which the drug was sold, distributed or administered.
Non-application
(2) Subsection (1) does not apply to a pharmacist who sells or distributes a prescription drug under subsection 178(1) or 178.1(1).
26 Subsection 178(1) of the Regulations is replaced by the following:
Sale and distribution for emergency purposes
178 (1) Subject to section 174, a pharmacist may sell or distribute a prescription drug for emergency purposes to another pharmacist in accordance with a written order that is signed and dated by the other pharmacist.
27 The Regulations are amended by adding the following after section 178:
Sale and distribution — no emergency
178.1 (1) Subject to section 174, a pharmacist may, in circumstances other than an emergency, sell or distribute a prescription drug to another pharmacist, in accordance with a written order that is signed and dated by the other pharmacist, if
- (a) they do so for the purpose of fulfilling a prescription received by the other pharmacist; or
- (b) they are ceasing to practise at the place where the drug is sold or distributed.
Signature
(2) Before selling or distributing the prescription drug, the pharmacist receiving the order must verify the signature, if it is unknown to them.
Record keeping
(3) The pharmacist who sells or distributes the prescription drug and the pharmacist to whom it is sold or distributed must each retain a record of the following information:
- (a) in the case of the pharmacist who sells or distributes the drug,
- (i) their name,
- (ii) the name and address of the pharmacist to whom they sell or distribute the drug,
- (iii) the brand name, quantity and form of the drug, and
- (iv) the date of the sale or distribution of the drug; and
- (b) in the case of the pharmacist to whom the drug is sold or distributed,
- (i) their name,
- (ii) the name and address of the pharmacist who sells or distributes the drug to them,
- (iii) the brand name, quantity and form of the drug, and
- (iv) the date on which the drug is received.
28 Paragraph 181(4)(a) of the Regulations is replaced by the following:
- (a) has contravened section 171, subsection 172(1) or (2), section 174, 175 or 176 or subsection 178(1) or 178.1(1) or (2);
29 (1) The portion of subsection 184(1) of the French version of the Regulations before paragraph (a) is replaced by the following:
Retour et destruction
184 (1) Le praticien est autorisé à vendre ou à distribuer une drogue contenant du cannabis aux personnes ci-après conformément à une commande écrite :
(2) Paragraph 184(2)(a) of the Regulations is replaced by the following:
- (a) the quantity and strength per unit of the drug as well as its proper name or common name or, in the case of a prescription drug, its brand name; and
(3) Paragraph 184(3)(a) of the Regulations is replaced by the following:
- (a) its form, quantity and strength per unit as well as its proper name or common name or, in the case of a prescription drug, its brand name;
30 The portion of section 186 of the Regulations before paragraph (a) is replaced by the following:
Record keeping
186 A practitioner who sells or distributes a drug containing cannabis to an individual for self-administration or for administration to an animal must, whether or not the practitioner charges for the drug, retain a record showing its proper name or common name — or, in the case of a prescription drug, its brand name — as well as the quantity of the drug sold or distributed, the name and address of the individual to whom and the date on which it was sold or distributed, if the quantity of the drug exceeds
31 (1) The portion of paragraph 189(1)(a) of the Regulations before subparagraph (i) is replaced by the following:
- (a) the following persons must not sell or distribute any drug containing cannabis to the practitioner:
(2) Paragraphs 189(4)(b), (c) and (d) of the Regulations are replaced by the following:
- (b) has, on more than one occasion, self-administered a drug containing cannabis under a self-directed prescription or order or, in the absence of a prescription or order, contrary to accepted professional practice;
- (c) has, on more than one occasion, distributed or administered a drug containing cannabis to their spouse, common-law partner, parent or child, including a child adopted in fact, contrary to accepted professional practice; or
- (d) is unable to account for the quantity of drugs containing cannabis for which the practitioner was responsible under this Part or Part 9.
(3) Subparagraph 189(5)(c)(iii) of the Regulations is replaced by the following:
- (iii) whether the actions of the practitioner pose a significant risk to public health or public safety, including the risk of any drug containing cannabis being diverted to an illicit market or activity.
32 (1) Subparagraph 191(a)(i) of the Regulations is replaced by the following:
- (i) the brand name and quantity of the drug,
(2) The portion of paragraph 191(b) of the Regulations before subparagraph (ii) is replaced by the following:
- (b) with respect to a prescription drug that is sold, distributed or administered by the hospital,
- (i) the name of the patient for whom or animal for which the drug was sold, distributed or administered,
33 The portion of section 192 of the Regulations before paragraph (a) is replaced by the following:
Security obligations
192 An individual in charge of a hospital must, with respect to a prescription drug for which the hospital is responsible,
34 (1) Subparagraphs 193(3)(a)(i) and (ii) of the Regulations are replaced by the following:
- (i) the drug is sold or distributed in accordance with a written order signed and dated by the pharmacist in charge of the pharmacy in the other hospital or by a practitioner who is authorized by the individual in charge of the other hospital to sign the order, and
- (ii) the person who sells or distributes the drug verifies the signature of the pharmacist or the practitioner, if it is unknown to them;
(2) Subparagraphs 193(3)(b)(i) and (ii) of the Regulations are replaced by the following:
- (i) the drug is sold or distributed in accordance with a written order signed and dated by the pharmacist in charge of the pharmacy in the other hospital or by a practitioner who is authorized by the individual in charge of the other hospital to sign the order, and
- (ii) the person who sells or distributes the drug verifies the signature of the pharmacist or the practitioner, if that signature is unknown to them; and
(3) Paragraph 193(3)(c) of the English version of the Regulations is replaced by the following:
- (c) an individual who is exempt under section 140 of the Act with respect to the drug and who is employed in a research laboratory in the hospital for the purpose of research.
35 (1) The portion of subsection 194(1) of the French version of the Regulations before paragraph (a) is replaced by the following:
Retour et destruction
194 (1) Malgré le paragraphe 193(2), la vente ou la distribution d’une drogue sur ordonnance aux personnes ci-après peut être autorisée par l’individu chargé de l’hôpital conformément à une commande écrite :
(2) Paragraph 194(2)(a) of the Regulations is replaced by the following:
- (a) the brand name, quantity and strength per unit of the drug; and
(3) Paragraph 194(3)(b) of the English version of the Regulations is replaced by the following:
- (b) the name and the address of the person to which it was sold or distributed; and
36 The Regulations are amended by adding the following after section 195:
Licensed Dealers
Record keeping — drug received
195.1 A licensed dealer who receives a drug containing cannabis must enter the following in a record retained for such purposes:
- (a) the proper name or common name of the drug or, in the case of a prescription drug, its brand name and drug identification number;
- (b) the form, quantity and strength per unit of the drug received;
- (c) the name and address of the person from whom the drug was received; and
- (d) the date of receipt.
Sale or distribution for destruction
195.2 (1) A licensed dealer, other than a licensed dealer specialized in destruction, may sell or distribute a drug containing cannabis in accordance with a written order to a licensed dealer specialized in destruction, if the drug is sold or distributed for the purpose of its destruction.
Written order
(2) The written order must contain
- (a) the proper name or common name of the drug or, in the case of a prescription drug, its brand name and drug identification number;
- (b) the quantity and strength per unit of the drug; and
- (c) an attestation that the sole purpose of the order is the destruction of the drug and that is signed and dated by, or on behalf of, the licensed dealer specialized in destruction.
Record keeping
(3) The licensed dealer referred to in subsection (1) that sells or distributes the drug must prepare a record that sets out
- (a) the proper name or common name of the drug or, in the case of a prescription drug, its brand name and drug identification number;
- (b) the form, quantity and strength per unit of the drug;
- (c) the name and address of the person to which it was sold or distributed; and
- (d) the date on which it was sold or distributed.
Retention period
195.3 The licensed dealer must retain the records referred to in section 195.1 and subsection 195.2(3) for at least two years after the day on which they are prepared.
DIVISION 3
Importation and Exportation by Travellers
Importation
195.4 On entering Canada, an individual may import a drug containing cannabis that is in their actual possession or that forms part of their baggage if
- (a) the individual is importing the drug
- (i) for their own use,
- (ii) for the use and on behalf of an accompanying individual, or
- (iii) for administration to an animal for which the individual is responsible and that is accompanying the individual;
- (b) the drug is declared to a customs officer at the port of entry into Canada;
- (c) the drug is in a container carrying a label on which the following information appears:
- (i) the name of the individual for whom or animal for which the drug was lawfully obtained,
- (ii) the name of the medical professional who authorized the drug to be obtained,
- (iii) the proper name or common name of the drug or, in the case of a prescription drug, its brand name and, if any, its drug identification number,
- (iv) the form, quantity and strength per unit of the drug, and
- (v) the daily dose authorized by the medical professional; and
- (d) the imported quantity of the drug does not exceed a 90-day supply required to treat a condition, based on the daily dose shown on the label.
Exportation
195.5 On departing Canada, an individual may export a drug containing cannabis that is in their actual possession or that forms part of their baggage if
- (a) the individual is exporting the drug
- (i) for their own use,
- (ii) for the use and on behalf of an accompanying individual, or
- (iii) for administration to an animal for which the individual is responsible and that is accompanying the individual;
- (b) the drug is in a container carrying a label on which the following information appears:
- (i) the name of the individual for whom or animal for which the drug was lawfully obtained,
- (ii) the name of the medical professional who authorized the drug to be obtained,
- (iii) the proper name or common name of the drug or, in the case of a prescription drug, its brand name and, if any, its drug identification number,
- (iv) the form, quantity and strength per unit of the drug, and
- (v) the daily dose authorized by the medical professional; and
- (c) the exported quantity of the drug does not exceed a 90-day supply required to treat a condition, based on the daily dose shown on the label.
37 Section 196 of the Regulations is repealed.
38 Sections 198 and 199 of the Regulations are replaced by the following:
Exemption — section 21 of Act
198 A person is exempt from the application of section 21 of the Act if they display, refer to or otherwise use the brand name of a combination product, or the name of the holder of the drug identification number for the product, directly or indirectly in a promotion that is used in the sponsorship of a person, entity, event, activity or facility.
Exemption — section 22 of Act
199 A person is exempt from the application of section 22 of the Act if they display on a facility, as part of the name of the facility or otherwise, if the facility is used for a sports or cultural event or activity, the brand name of a combination product or the name of the holder of the drug identification number for the product.
39 Subparagraphs 205(c)(iv) and (v) of the Regulations are replaced by the following:
- (iv) in the case of a drug containing cannabis, other than a prescription drug, its proper name or common name,
- (v) in the case of a prescription drug, its brand name and drug identification number,
- (vi) the quantity of the cannabis, and
- (vii) the percentage of THC w/w and CBD w/w of the cannabis, except in the case of cannabis plants and cannabis plant seeds;
40 Subparagraphs 209(c)(iv) and (v) of the Regulations are replaced by the following:
- (iv) in the case of a drug containing cannabis, other than a prescription drug, its proper name or common name,
- (v) in the case of a prescription drug, its brand name and drug identification number,
- (vi) the quantity of the cannabis, and
- (vii) the percentage of THC w/w and CBD w/w of the cannabis, except in the case of cannabis plants and cannabis plant seeds.
41 Subparagraphs 214(c)(iv) and (v) of the Regulations are replaced by the following:
- (iv) in the case of a drug containing cannabis, other than a prescription drug, its proper name or common name,
- (v) in the case of a prescription drug, its brand name and drug identification number,
- (vi) the quantity of the cannabis, and
- (vii) the percentage of THC w/w and CBD w/w of the cannabis, except in the case of cannabis plants and cannabis plant seeds;
42 Subparagraphs 218(c)(iv) and (v) of the Regulations are replaced by the following:
- (iv) in the case of a drug containing cannabis, other than a prescription drug, its proper name or common name,
- (v) in the case of a prescription drug, its brand name and drug identification number,
- (vi) the quantity of the cannabis, and
- (vii) the percentage of THC w/w and CBD w/w of the cannabis, except in the case of cannabis plants and cannabis plant seeds.
43 Paragraph 224(2)(c) of the Regulations is replaced by the following:
- (c) in the case of a drug containing cannabis
- (i) its proper name or common name or, in the case of a prescription drug, its brand name and drug identification number, and
- (ii) its strength per unit.
44 Paragraph 225(2)(c) of the Regulations is replaced by the following:
- (c) in the case of a drug containing cannabis,
- (i) its proper name or common name or, in the case of a prescription drug, its brand name and drug identification number, and
- (ii) its strength per unit.
45 Paragraph 226(1)(g) of the Regulations is replaced by the following:
- (g) in the case of a drug containing cannabis,
- (i) its proper name or common name or, in the case of a prescription drug, its brand name and drug identification number, and
- (ii) the form of the drug and its strength per unit; and
46 Paragraph 227(1)(g) of the Regulations is replaced by the following:
- (g) in the case of a drug containing cannabis,
- (i) its proper name or common name or, in the case of a prescription drug, its brand name and drug identification number, and
- (ii) the form of the drug and its strength per unit;
47 Paragraph 229(1)(a) of the Regulations is replaced by the following:
- (a) a description of the cannabis, including,
- (i) in the case of a drug containing cannabis, other than a prescription drug, its proper name or common name, and
- (ii) in any other case, its brand name, if applicable;
48 (1) Subparagraphs 237(1)(a)(ii) to (iv) of the Regulations are replaced by the following:
- (ii) in the case of a drug containing cannabis, other than a prescription drug, its proper name or common name,
- (iii) in the case of a prescription drug, its brand name and drug identification number,
- (iv) the quantity used and, if applicable, the lot or batch number,
- (v) the date on which it is used, and
- (vi) the purpose and a brief description of the activity;
(2) Subparagraph 237(1)(b)(i) of the Regulations is replaced by the following:
- (i) its description, including, in the case of a drug containing cannabis, its proper name or common name,
49 Paragraph 247(2)(a) of the Regulations is replaced by the following:
- (a) a description of the cannabis, including
- (i) in the case of a drug containing cannabis, other than a prescription drug, its proper name or common name,
- (ii) in the case of a prescription drug, its brand name and drug identification number, and
- (iii) in any other case, its brand name, if applicable;
50 (1) Paragraph 255(a) of the Regulations is replaced by the following:
- (a) subject to subparagraph 261(2)(a)(i), a registration number has been issued for the test kit and the number has not been cancelled;
(2) Clause 255(b)(ii)(A) of the Regulations is replaced by the following:
- (A) the name and address of the manufacturer or assembler or, if applicable, of the person for which the test kit was manufactured or assembled further to a custom order, and
(3) Paragraph 255(c) of the English version of the Regulations is replaced by the following:
- (c) the test kit is sold, imported or exported for a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose.
51 Paragraph 256(b) of the English version of the Regulations is replaced by the following:
- (b) distribute it for a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose.
52 (1) Paragraphs 258(1)(b) and (c) of the Regulations are replaced by the following:
- (b) a detailed description of the design and construction of the test kit;
- (c) a description of the proposed use of the test kit;
(2) Paragraph 258(1)(e) of the Regulations is replaced by the following:
- (e) with respect to any other substance contained in the test kit, its name, form and quantity; and
(3) Subsection 258(2) of the Regulations is replaced by the following:
Signature and attestation
(2) The application must
- (a) be signed and dated by the individual authorized by the applicant for that purpose; and
- (b) include an attestation by that individual that all of the information provided in support of the application is correct and complete to the best of their knowledge.
53 Sections 260 and 261 of the Regulations are replaced by the following:
Issuance of a registration number
260 (1) Subject to section 260.1, the Minister must, after examining the information and documents required under sections 258 and 259, issue to the applicant a document that sets out a registration number for the test kit if the Minister determines that the test kit will only be used for a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose.
Alteration of documents
(2) A person must not alter or deface in any manner the document that sets out the registration number.
Refusal
260.1 The Minister must refuse to issue a registration number for a test kit if the Minister has reasonable grounds to believe that
- (a) the test kit poses a risk to public health or safety, including the risk of the cannabis in the test kit being diverted to an illicit market or activity, because
- (i) the total amount of the cannabis is too high, or
- (ii) the adulterating or denaturing agent in the test kit is not likely to prevent or deter consumption or administration of the cannabis; or
- (b) the test kit will be used for a purpose other than one referred to in subsection 260(1).
Cancellation
261 (1) The Minister must cancel the registration number of a test kit if
- (a) the Minister receives a notice from the person to which the document that sets out the registration number was issued, stating that manufacture or assembly of the test kit has ceased; or
- (b) the Minister has reasonable grounds to believe that one of the circumstances referred to in paragraph 260.1(a) or (b) exists.
Effect of cancellation
(2) The following rules apply when the registration number of a test kit is cancelled:
- (a) in the case of a test kit manufactured or assembled before a cancellation under paragraph (1)(a),
- (i) the sale, import and export remain authorized, and
- (ii) the registration number must remain on the label; and
- (b) in the case of a test kit manufactured or assembled either before or after a cancellation under paragraph (1)(b), the registration number must not be displayed on the label.
54 Section 263 of the Regulations is repealed.
55 The Regulations are amended by replacing “declaration” with “attestation”, with any necessary modifications, in the following provisions:
- (a) paragraph 20(2)(c);
- (b) paragraph 24(2)(c);
- (c) paragraph 33(2)(c);
- (d) paragraph 34(2)(b);
- (e) subparagraph 152(2)(c)(i); and
- (f) paragraph 153(2)(b).
56 The Regulations are amended by replacing “licensed dealer” with “licensed dealer specialized in destruction” in the following provisions:
- (a) paragraph 143(1)(f); and
- (b) the portion of subsection 146(2) before paragraph (a) and the portion of subsection 146(6) before paragraph (a).
57 The Regulations are amended by replacing “a written statement that affirms” with “an attestation” in the following provisions:
- (a) paragraph 172(2)(b);
- (b) paragraph 184(2)(b); and
- (c) paragraph 194(2)(b).
58 The Regulations are amended by replacing “Narcotic Control Regulations” with “former Narcotic Control Regulations” in the following provisions:
- (a) clause 180(a)(ii)(D);
- (b) subparagraphs 181(3)(c)(iii) and (5)(c)(ii);
- (c) clause 188(a)(ii)(D);
- (d) subparagraphs 189(3)(c)(iii) and (5)(c)(ii);
- (e) clause 333(a)(iii)(D) and subparagraph 333(a)(iv);
- (f) subparagraph 335(2)(c)(v) and paragraph 335(4)(e);
- (g) clause 343(a)(iii)(D) and subparagraph 343(a)(iv);
- (h) paragraph 344(3)(c);
- (i) clause 353(1)(a)(iii)(D) and subparagraph 353(1)(a)(iv);
- (j) subsections 355(1) and (2) and the heading of column 1 of the table to section 355; and
- (k) subsections 361(2) and (3).
59 The French version of the Regulations is amended by replacing « nécessaire », « nécessaire d’essai » and « nécessaires d’essai » respectively with « trousse », « trousse d’essai » and « trousses d’essai », with any necessary modifications, in the following provisions:
- (a) paragraph 4(1)(b);
- (b) subsection 19(4);
- (c) paragraph 22(1)(b);
- (d) the heading of Part 13;
- (e) sections 253 and 254;
- (f) the portion of section 255 before paragraph (a), the portion of paragraph 255(b) before subparagraph (i), the portion of subparagraph 255(b)(ii) before clause (A) and paragraph 255(c);
- (g) sections 256 and 257;
- (h) the portion of subsection 258(1) before paragraph (b), the portion of paragraph 258(1)(d) before subparagraph (i) and paragraph 258(1)(f);
- (i) the portion of section 262 before paragraph (a); and
- (j) item 3 of the table to section 355.
60 The French version of the Regulations is amended by replacing « imposer » with « infliger » in the following provisions:
- (a) subparagraphs 151(1)(a)(ii) and (b)(ii);
- (b) subparagraphs 152(2)(b)(ii) and (iii);
- (c) paragraphs 311(2)(c) and (d); and
- (d) subparagraph 312(4)(c)(i) and paragraph 312(4)(d).
61 The English version of the Regulations is amended by replacing “statement” with “attestation”, with any necessary modifications, in the following provisions:
- (a) subsections 229(2) and (3);
- (b) subsection 273(3);
- (c) the portion of paragraph 279(2)(g) before subparagraph (i), subparagraphs 279(2)(g)(iii), (v) and (vi), the portion of paragraph 279(3)(e) before subparagraph (i) and subparagraphs 279(3)(e)(v) and (vi);
- (d) the portion of paragraph 285(2)(e) before subparagraph (i) and subparagraphs 285(2)(e)(iii) and (iv);
- (e) section 307; and
- (f) subsection 312(5).
Coming into Force
62 These Regulations come into force on the 365th day after the day on which they are published in the Canada Gazette, Part II.
Terms of use and Privacy notice
Terms of use
It is your responsibility to ensure that the comments you provide do not:
- contain personal information
- contain protected or classified information of the Government of Canada
- express or incite discrimination on the basis of race, sex, religion, sexual orientation or against any other group protected under the Canadian Human Rights Act or the Canadian Charter of Rights and Freedoms
- contain hateful, defamatory, or obscene language
- contain threatening, violent, intimidating or harassing language
- contain language contrary to any federal, provincial or territorial laws of Canada
- constitute impersonation, advertising or spam
- encourage or incite any criminal activity
- contain external links
- contain a language other than English or French
- otherwise violate this notice
The federal institution managing the proposed regulatory change retains the right to review and remove personal information, hate speech, or other information deemed inappropriate for public posting as listed above.
Confidential Business Information should only be posted in the specific Confidential Business Information text box. In general, Confidential Business Information includes information that (i) is not publicly available, (ii) is treated in a confidential manner by the person to whose business the information relates, and (iii) has actual or potential economic value to the person or their competitors because it is not publicly available and whose disclosure would result in financial loss to the person or a material gain to their competitors. Comments that you provide in the Confidential Business Information section that satisfy this description will not be made publicly available. The federal institution managing the proposed regulatory change retains the right to post the comment publicly if it is not deemed to be Confidential Business Information.
Your comments will be posted on the Canada Gazette website for public review. However, you have the right to submit your comments anonymously. If you choose to remain anonymous, your comments will be made public and attributed to an anonymous individual. No other information about you will be made publicly available.
Comments will remain posted on the Canada Gazette website for at least 10 years.
Please note that public email is not secure, if the attachment you wish to send contains sensitive information, please contact the departmental email to discuss ways in which you can transmit sensitive information.
Privacy notice
The information you provide is collected under the authority of the Financial Administration Act, the Department of Public Works and Government Services Act, the Canada–United States–Mexico Agreement Implementation Act,and applicable regulators’ enabling statutes for the purpose of collecting comments related to the proposed regulatory changes. Your comments and documents are collected for the purpose of increasing transparency in the regulatory process and making Government more accessible to Canadians.
Personal information submitted is collected, used, disclosed, retained, and protected from unauthorized persons and/or agencies pursuant to the provisions of the Privacy Act and the Privacy Regulations. Individual names that are submitted will not be posted online but will be kept for contact if needed. The names of organizations that submit comments will be posted online.
Submitted information, including personal information, will be accessible to Public Services and Procurement Canada, who is responsible for the Canada Gazette webpage, and the federal institution managing the proposed regulatory change.
You have the right of access to and correction of your personal information. To seek access or correction of your personal information, contact the Access to Information and Privacy (ATIP) Office of the federal institution managing the proposed regulatory change.
You have the right to file a complaint to the Privacy Commission of Canada regarding any federal institution’s handling of your personal information.
The personal information provided is included in Personal Information Bank PSU 938 Outreach Activities. Individuals requesting access to their personal information under the Privacy Act should submit their request to the appropriate regulator with sufficient information for that federal institution to retrieve their personal information. For individuals who choose to submit comments anonymously, requests for their information may not be reasonably retrievable by the government institution.